976 ORAL Ovarian toxicity after high dose chemotherapy without total body irradiation and without busulfan

Abstract

This chapter describes the potential test systems for chemotherapeutic agents against prostatic cancer. The testing of agents potentially useful in the therapy of prostatic cancer is facing the lack of an appropriate in vivo model system for cancer of the prostate in a suitable animal in which such drugs could be tested. The development of chemotherapeutic agents against prostatic cancer assumes a crucial aspect in this disease, with full recognition and dependency on the value and implications of hormonal therapy in cancer of the prostate. The effects of estrogens on the 5α-RA are less clearly understood than those of androgens. The administration of estrogens to intact animals does decrease greatly the 5α-RA. It is found that cyclophosphamide, 5-FU1 isophosphamide, adriamycin, diglycolaldehyde, bleomycin, and CCNU caused the largest decreases in prostatic weight. Hydroxyurea and thiotepa led to some gain in body weight and gains in prostatic weights. It is shown that thiotepa and hydroxyurea also cause noncompetitive activation of 5α-RA in the dorsolateral and ventral glands of the rat.